## Prior notification of a concentration

## (Case M.8675 — CVC/Teva's Women's Health Business)

**(Text with EEA relevance)**

(2017/C 396/12)

1. On 16 November 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— CVC Capital Partners SICAV-FIS SA ('CVC', Luxembourg)

— International Women's Health Business of Teva Pharmaceutical Industries Ltd ('Target Business', Israel).

CVC acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the Target Business.

The concentration is accomplished by way of purchase of assets.

2. The business activities of the undertakings concerned are:

— CVC: management of and provision of advice to investment funds and platforms,

— Target Business: the production and supply of women's health pharmaceutical products worldwide, with the exception of the US.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.8675 — CVC/Teva's Women's Health Business

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

E-mail: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').